Two pricing structures, two different ways the total adds up. Flat-rate folds everything into one medication price; membership-fee splits a base subscription from a medication add-on.
| Factor | Flat-rate (e.g. Henry Meds, NexLife) | Membership + add-on (e.g. Mochi) |
|---|---|---|
| How you pay | One price, all-in | Base membership + medication add-on |
| Predictability | High — same at every dose | Total depends on add-on + membership |
| What the extra buys | Usually meds + basic support | Often more structured coaching/programming |
| Best for | Lowest, predictable medication cost | Those who value bundled services |
Neither model is inherently cheaper — add the membership to the add-on and compare the total against the flat price at your dose. A membership that bundles real coaching can be worth it; one that doesn’t is just overhead. See total monthly cost.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.